Amgen and AstraZeneca's TEZSPIRE Meets Phase 3 Endpoints in Eosinophilic Esophagitis Trial

Key Facts

1The Phase 3 CROSSING trial showed TEZSPIRE demonstrated statistically significant improvements in treating eosinophilic esophagitis.

Amgen and AstraZeneca announced that TEZSPIRE demonstrated statistically significant improvements in treating eosinophilic esophagitis (EoE) based on results from the Phase 3 CROSSING trial. PR Newswire reported that the drug met its co-primary and key secondary endpoints in adolescent and adult patients with uncontrolled EoE over a 52-week period. The trial results showed sustained histologic remission and symptom improvement compared to the placebo group.

AMGN closed at $424.94 on October 19, 2026, while AZN closed at $163.95 on the same date. These positive clinical milestones for the co-developed drug support the long-term valuation of both companies within the pharmaceutical sector, as the trial confirmed the efficacy of TEZSPIRE in achieving total endoscopic remission for a significant portion of the participants.